Volume 21, Number 4—April 2015
Synopsis
Hantavirus Pulmonary Syndrome , Southern Chile, 1995–2012
Table 3
Vital signs and laboratory results for 80 hantavirus pulmonary syndrome patients admitted to Hospital Puerto Montt, Puerto Montt, Chile, 1995–2012
Parameter | Median ± SD (range) |
---|---|
Laboratory value* | |
Hematocrit, %, n = 74 | 47 ± 7 (32–72) |
Platelets × 103/μL, n = 75 | 67,505 ± 42,717 (14,000–238,000) |
Leukocytes × 103 cells/μL, n = 74 | 13,520 ± 9,971 (2,800–59,400) |
Creatinine, mg/dL, n = 70 | 1.41 ± 0.97 (0.6–6.6) |
Bilirubin, mg/dL, n = 64 | 0.62 ± 0.70 (0.03–5.9) |
Aspartate aminotransferase, U/L, n = 66 | 245.2 ± 178.2 (26–705) |
Alanine aminotransferase, U/L, n = 44 | 172.2 ± 134.7 (11–536) |
Prothrombin, %, n = 56 | 81.1 ± 22.4 (13–100) |
Vital signs | |
Temperature, °C, n = 75 | 37.7 ± 1.1 (35–40.5) |
Pulse, beats/min, n = 76 | 109,13 ± 22(61–158) |
Respirations, breaths/min, n = 63 | 30.6 ± 9.5 (16–60) |
Systolic blood pressure, <90 mm Hg, n = 79 | 22.5 % |
*Reference values are as follows: hematocrit 37%–47%, platelets 140–440× 103/μL, leucocytes 4,1–10.9× 103 cells/μL, creatinine 0.5–0.9 mg/dL, bilirubin 0.05–1.0 mg/dL, glutamic-oxalacetic transaminase 10–50 U/L, glutamic-pyruvic transaminase <35 U/L, prothombin 70%–120%.
Page created: March 17, 2015
Page updated: March 17, 2015
Page reviewed: March 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.